{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:50:39Z","timestamp":1778482239682,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02363991"],"award-info":[{"award-number":["GR-2016-02363991"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00259-023-06483-y","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T07:02:36Z","timestamp":1698476556000},"page":"907-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Diagnostic accuracy of fully hybrid [68Ga]Ga-PSMA-11 PET\/MRI and [68Ga]Ga-RM2 PET\/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial"],"prefix":"10.1007","volume":"51","author":[{"given":"Samuele","family":"Ghezzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Mapelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Samanes Gajate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Brembilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Bezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazareno","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Scifo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"6483_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263\u201382.","journal-title":"Eur Urol"},{"key":"6483_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.juro.2015.04.103","volume":"194","author":"G Ploussard","year":"2015","unstructured":"Ploussard G, Almeras C, Briganti A, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983\u20138.","journal-title":"J Urol"},{"key":"6483_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6483_CR4","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596\u2013604.","journal-title":"J Nucl Med"},{"key":"6483_CR5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316.","journal-title":"Lancet"},{"key":"6483_CR6","unstructured":"Mottet N, Cornford P,\u00a0Van den Bergh RCN, Briers E, Eberli D, De Meerleer G, De Santis M, Gillessen S, Grummet J, et al.\u00a0EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer 2023. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Urological-infections-2023.pdf."},{"key":"6483_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bju.14944","volume":"125","author":"HB Luiting","year":"2020","unstructured":"Luiting HB, van Leeuwen PJ, Busstra MB, et al. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int. 2020;125:206\u201314.","journal-title":"BJU Int"},{"key":"6483_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/cancers14020334","volume":"14","author":"P Mapelli","year":"2022","unstructured":"Mapelli P, Ghezzo S, Samanes Gajate AM, et al. 68Ga-PSMA and 68Ga-DOTA-RM2 PET\/MRI in recurrent prostate cancer: diagnostic performance and association with clinical and histopathological data. Cancers (Basel). 2022;14:334.","journal-title":"Cancers (Basel)"},{"key":"6483_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, et al. Assessment of 68 Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer. JAMA Oncol. 2019;5:856.","journal-title":"JAMA Oncol"},{"key":"6483_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","volume":"74","author":"S Han","year":"2018","unstructured":"Han S, Woo S, Kim YJ, Suh CH. Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018;74:179\u201390.","journal-title":"Eur Urol"},{"key":"6483_CR11","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674\u201382.","journal-title":"Clin Cancer Res"},{"key":"6483_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1053\/j.semnuclmed.2019.02.001","volume":"49","author":"E Mena","year":"2019","unstructured":"Mena E, Lindenberg LM, Choyke PL. New targets for PET molecular imaging of prostate cancer. Semin Nucl Med. 2019;49:326\u201336.","journal-title":"Semin Nucl Med"},{"key":"6483_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/pros.22743","volume":"74","author":"M K\u00f6rner","year":"2014","unstructured":"K\u00f6rner M, Waser B, Rehmann R, Reubi JC. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2014;74:217\u201324.","journal-title":"Prostate"},{"key":"6483_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00259-017-3702-8","volume":"44","author":"G Wieser","year":"2017","unstructured":"Wieser G, Popp I, Christian Rischke H, et al. Diagnosis of recurrent prostate cancer with PET\/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET\/CT. Eur J Nucl Med Mol Imaging. 2017;44:1463\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6483_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","volume":"62","author":"L Baratto","year":"2021","unstructured":"Baratto L, Song H, Duan H, et al. PSMA- and GRPR-targeted PET: results from 50 patients with biochemically recurrent prostate cancer. J Nucl Med. 2021;62:1545\u20139.","journal-title":"J Nucl Med"},{"key":"6483_CR16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/diagnostics11112068","volume":"11","author":"P Mapelli","year":"2021","unstructured":"Mapelli P, Ghezzo S, Samanes Gajate AM, et al. Preliminary results of an ongoing prospective clinical trial on the use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET\/MRI in staging of high-risk prostate cancer patients. Diagnostics. 2021;11:2068.","journal-title":"Diagnostics"},{"key":"6483_CR17","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2967\/jnumed.117.198192","volume":"58","author":"A Iagaru","year":"2017","unstructured":"Iagaru A. Will GRPR compete with PSMA as a target in prostate cancer? J Nucl Med. 2017;58:1883\u20134.","journal-title":"J Nucl Med"},{"key":"6483_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cpet.2022.07.006","volume":"17","author":"H Duan","year":"2022","unstructured":"Duan H, Iagaru A. PET imaging using gallium-68 (68Ga) RM2. PET Clin. 2022;17:621\u20139.","journal-title":"PET Clin"},{"key":"6483_CR19","doi-asserted-by":"publisher","unstructured":"Liu FY, Sheng TW, Tseng JR, Yu KJ, Tsui KH, Pang ST, Wang LJ, Lin G. Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET-CT vs PET-MRI. Br J Radiol. 2022;95(1131):20210728. https:\/\/doi.org\/10.1259\/bjr.20210728.","DOI":"10.1259\/bjr.20210728"},{"key":"6483_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","volume":"48","author":"L Evangelista","year":"2021","unstructured":"Evangelista L, Zattoni F, Cassarino G, et al. PET\/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:859\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6483_CR21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","volume":"44","author":"MT Freitag","year":"2017","unstructured":"Freitag MT, Radtke JP, Afshar-Oromieh A, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776\u201387.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6483_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6483_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2019.04.004","volume":"130","author":"MA Hoffmann","year":"2019","unstructured":"Hoffmann MA, Wieler HJ, Baues C, et al. The impact of 68Ga-PSMA PET\/CT and PET\/MRI on the management of prostate cancer. Urology. 2019;130:1\u201312.","journal-title":"Urology"},{"key":"6483_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","volume":"61","author":"I Sonni","year":"2020","unstructured":"Sonni I, Eiber M, Fendler WP, et al. Impact of 68 Ga-PSMA-11 PET\/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med. 2020;61:1153\u201360.","journal-title":"J Nucl Med"},{"key":"6483_CR25","doi-asserted-by":"publisher","unstructured":"Huo H, Shen S, He D, Liu B, Yang F. Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and 68Ga-PSMA-11 PET\/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies. Prostate Cancer Prostatic\u00a0Dis. 2023;26(1):16\u201324. https:\/\/doi.org\/10.1038\/s41391-022-00581-y.","DOI":"10.1038\/s41391-022-00581-y"},{"key":"6483_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40644-022-00489-9","volume":"22","author":"PA Glemser","year":"2022","unstructured":"Glemser PA, Rotkopf LT, Ziener CH, et al. Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer. Cancer Imaging. 2022;22:53.","journal-title":"Cancer Imaging"},{"key":"6483_CR27","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00330-021-08140-0","volume":"32","author":"S Jentjens","year":"2022","unstructured":"Jentjens S, Mai C, Ahmadi Bidakhvidi N, et al. Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET\/MR versus PET\/CT in patients with biochemically recurrent prostate cancer. Eur Radiol. 2022;32:901\u201311.","journal-title":"Eur Radiol"},{"key":"6483_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13550-020-00652-y","volume":"10","author":"TF Fassbender","year":"2020","unstructured":"Fassbender TF, Schiller F, Zamboglou C, et al. Voxel-based comparison of [68Ga]Ga-RM2-PET\/CT and [68Ga]Ga-PSMA-11-PET\/CT with histopathology for diagnosis of primary prostate cancer. EJNMMI Res. 2020;10:62.","journal-title":"EJNMMI Res"},{"key":"6483_CR29","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach","year":"2006","unstructured":"Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol. 2006;65:965\u201374.","journal-title":"Int J Radiat Oncol"},{"key":"6483_CR30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","volume":"37","author":"E Demirci","year":"2016","unstructured":"Demirci E, Sahin OE, Ocak M, et al. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging. Nucl Med Commun. 2016;37:1169\u201379.","journal-title":"Nucl Med Commun"},{"key":"6483_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00259-019-04503-4","volume":"47","author":"L Baratto","year":"2020","unstructured":"Baratto L, Duan H, Laudicella R, et al. Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements. Eur J Nucl Med Mol Imaging. 2020;47:115\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6483_CR32","first-page":"1","volume":"2014","author":"F Barchetti","year":"2014","unstructured":"Barchetti F, Panebianco V. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int. 2014;2014:1\u201323.","journal-title":"Biomed Res Int"},{"key":"6483_CR33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2214\/AJR.14.14275","volume":"205","author":"K Kitajima","year":"2015","unstructured":"Kitajima K, Hartman RP, Froemming AT, et al. Detection of local recurrence of prostate cancer after radical prostatectomy using endorectal coil MRI at 3 T: addition of DWI and dynamic contrast enhancement to T2-weighted MRI. Am J Roentgenol. 2015;205:807\u201316.","journal-title":"Am J Roentgenol"},{"key":"6483_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.prnil.2017.05.002","volume":"6","author":"T Kwon","year":"2018","unstructured":"Kwon T, Kim JK, Lee C, et al. Discrimination of local recurrence after radical prostatectomy: value of diffusion-weighted magnetic resonance imaging. Prostate Int. 2018;6:12\u20137.","journal-title":"Prostate Int"},{"key":"6483_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1148\/radiol.11101996","volume":"262","author":"HA Vargas","year":"2012","unstructured":"Vargas HA, Wassberg C, Akin O, Hricak H. MR Imaging of treated prostate cancer. Radiology. 2012;262:26\u201342.","journal-title":"Radiology"},{"key":"6483_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ucl.2018.03.011","volume":"45","author":"S Gaur","year":"2018","unstructured":"Gaur S, Turkbey B. Prostate MR imaging for posttreatment evaluation and recurrence. Urol Clin N Am. 2018;45:467\u201379.","journal-title":"Urol Clin N Am"},{"key":"6483_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijrobp.2007.06.029","volume":"70","author":"MA Haider","year":"2008","unstructured":"Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol. 2008;70:425\u201330.","journal-title":"Int J Radiat Oncol"},{"key":"6483_CR38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2214\/ajr.167.6.8956585","volume":"167","author":"GJ Jager","year":"1996","unstructured":"Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. Am J Roentgenol. 1996;167:1503\u20137.","journal-title":"Am J Roentgenol"},{"key":"6483_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1148\/radiol.14132921","volume":"273","author":"HC Thoeny","year":"2014","unstructured":"Thoeny HC, Froehlich JM, Triantafyllou M, et al. Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted mr imaging. Radiology. 2014;273:125\u201335.","journal-title":"Radiology"},{"key":"6483_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, et al. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol. 2017;71:81\u201392.","journal-title":"Eur Urol"},{"key":"6483_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404.","journal-title":"Biometrika"},{"key":"6483_CR42","unstructured":"R Core Team (2019). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. 2019. https:\/\/www.R-project.org\/2019."},{"key":"6483_CR43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2967\/jnumed.115.168393","volume":"57","author":"R Minamimoto","year":"2016","unstructured":"Minamimoto R, Hancock S, Schneider B, et al. Pilot comparison of 68 Ga-RM2 PET and 68 Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer. J Nucl Med. 2016;57:557\u201362.","journal-title":"J Nucl Med"},{"key":"6483_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1055\/a-0990-8898","volume":"58","author":"S Hober\u00fcck","year":"2019","unstructured":"Hober\u00fcck S, Michler E, Wunderlich G, et al. 68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin. 2019;58:352\u201362.","journal-title":"Nuklearmedizin"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06483-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06483-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06483-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T21:30:14Z","timestamp":1705613414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06483-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6483"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06483-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of IRCCS San Raffaele Scientific Institute. All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave their informed consent to participate to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}